32 results about "Intermediary metabolite" patented technology

The invention provides a dye waste water treatment system which sequentially comprises a physico-chemical pretreatment system, an anaerobic tank, an aerobic tank and an advanced oxidation treatment system; dye waste water to be treated firstly enters into the physico-chemical pretreatment system to remove part chromaticity, sulphate and COD in the dye waste water, so as to ensure the pH, the alkalinity and the proper sulfate concentration which are needed by high-efficiency and stable running of later stage of anaerobic technique; after that, the dye waste water enters into the anaerobic tankto have anaerobic reaction and then enters the aerobic tank to have aerobic reaction; finally, the dye waste water enters into the advanced oxidation treatment system to remove the residual chromaticity and organic matter hard to degraded in the aerobic effluent as well as intermediate metabolite generated in the process of biological treatment. When being used for treating the dye waste water, especially the waste water having high salinity, sulfate, chromaticity and COD as well as higher concentration organic matter hard to degraded, the combined system has good treating effect and ensures the finally yielding water to reach the first-grade standard in GB4287-92 pollutant emission standards for textile dyeing and finishing industry.

The present invention provides a photobiological ethanol production and harvesting technology using greenhouse distillation systems with designer photosynthetic organisms, such as designer transgenic oxyphotobacteria. The designer oxyphotobacteria are created such that the endogenous photobiological regulation mechanism is tamed, and the reducing power (NADPH) and energy (ATP) acquired from the photosynthetic process are used for synthesis of ethanol (CH3CH2OH) directly from carbon dioxide (CO2) and water (H2O). The designer use of a pair of NADPH-dependent vs. NAD-dependent glyceralde-hyde-3-phosphate dehydrogenases in the pathway designs offers a special cyclic “transhydrogenase” redox-shuttle function to convert NADPH to NADH for enhanced photobiological ethanol production. Through combined use of a designer photosynthetic organism with a greenhouse distillation system, the waste solar heat associated with the photobiological ethanol-production process is utilized in harvesting the produced ethanol. In addition to production and harvesting of ethanol, use of the technology can also produce intermediate metabolites and freshwater from seawater.

The invention provides a dye waste water treatment method, comprising a materializing pre-treatment, an anaerobic treatment, an aerobic treatment, and an advanced oxidation treatment carried out in sequence, wherein the method comprises the steps of conducting a materializing pre-treatment to the object dye waste water to get rid of a part of chromaticity and COD for the anaerobic treatment and aerobic treatment, and then conducting an advanced oxidation treatment to the water discharged from the aerobic treatment to finally remove the degradation-refractory pollutant at the end of the waste water treatment and the intermediate metabolized substances produced in the process of biological treatment. Through the combined process of materializing pre-treatment, anaerobic treatment, aerobic treatment and advanced oxidation treatment, the invention can effectively treat difficultly degraded dye waste water and reduce the operation cost, thereby being capable of standardizing the indexes such as COD and chromaticity of the discharged water to the national norm simultaneously, solving the domestic current situation of difficulties in treating dye waste water, and being capable of meetingthe requirements of upgrading and restructuring the sewage treatment plant according to the increased standard of environment protection in the future.

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

The invention discloses an anti-blocking liquid used in surgery and a method for preparing the same. The anti-blocking liquid comprises 1 weight% carboxymethyl chitosan having molecular weight of 200000-300000 dalton and 30-100 weight% water for injection, which dynamics viscosity is 100~800 centipoise. The preparing method comprises: removing impurity protein pyrogen from the raw material; carboxymethyl-modification of chitin; purifying the carboxymethyl chitosan; preparing the anti-blocking liquid and the preparation thereof. Accordingly, the anti-blocking liquid has excellent biological barrier performance and histocompatibility, after applied on tissue wound surface, can prevent tissue tissue adhesion postoperation, which intermediary metabolite and final metabolite in human body are normal metabolites facilitating to be absorbed by the human body, without toxicity and acrimony. The anti-blocking liquid has abundance material sources with low cost and simple process, thus has broad application prospects in clinical medicine art.

The invention discloses a heterotrophic nitrification and aerobic denitrification Citrobacter species applicable to the treatment of wastewaters from industrial and agricultural production or domestic wastewater. The species is already collected in China General Microbiological Culture Collection Center under CGMCC No. 13434 and is applicable to biological denitrification of nitrogen-bearing water and biological degradation of various antibiotics in various water environments. Citrobacter freundii CFS06 herein is capable of biologically removing organic or inorganic nitrogen and is discovered to tolerate phenols in water and effectively degrade the same. The results of heterotrophic nitrification performance measurement show that the above Acinetobacter, Citrobacter freundii CFS06, has high removal rate for organic and inorganic ammonia nitrogen, with zero accumulation of intermediate metabolites, nitrates and nitrites; the species is capable of denitrifying nitrates under aerobic condition, has low requirement on C / N nutrition, has great breeding capacity in wastewater environments, and has a promising application prospect in terms of green treatment of river channel industrial contaminants owing to its tolerance and degradation for phenols.

It is an object of the present invention to provide a bacterial strain that can decrease the amount of an intermediate Compound P converted into Metabolite M and efficiently accumulate Compound P in a medium that is not supplemented with Metabolite M or the final product generated from Metabolite M. The present invention provides a prokaryotic organism having all features (a) to (d) as defined in the specification so as to accumulate Compound P by regulating expression level of Enzyme X that converts Compound P as an intermediate metabolite into Metabolite M in a biosynthetic pathway in which Metabolite M indispensable for the growth is produced from a carbon source.

Pyruvic acid is one important intermediate metabolite of glycometabolism of living body, has certain health functions and is the material for synthesizing L-tryptophane, L-tyrosine, L-dopa and other products. The present invention is the method of producing pyruvic acid via fermentation of glycose with dermoid trichocyst yeast. Inside simple culture medium without vitamins and amino acids added, pyruvic acid over 40 g / L may be obtained. The present invention has low material cost and excellent application foreground.

The invention relates to the technical field of synthetic biology, in particular to a genetic element, an expression vector and application of the genetic element and the expression vector. The invention provides a novel method for improving the synthesis of fatty hydrocarbon microorganisms: the fatty hydrocarbon synthesis capability of escherichia coli is improved by dynamically balancing accumulation and conversion of a key intermediate metabolite, namely fatty aldehyde. In order to achieve this purpose, ADO is helped to balance the synthesis and conversion of the fatty aldehyde through a competition path by synergistically expressing a synthesis process of fatty alcohol; then, three modules for fatty acid synthesis, lipid degradation and electron transfer, which are related to dynamic balance of the fatty aldehyde, are matched with a fatty hydrocarbon synthesis module, and finally the artificial synthesis of high-yield fatty hydrocarbon from engineering escherichia coli is realized.

The invention provides a recombinant bacillus subtilis, construction method and use thereof, wherein the cell's own FMMs are used as a space scaffold, and a multi-enzyme complex is constructed from specific marker proteins FloA and FloT, such that an artificial substrate channel is formed, and the cell metabolic burden is effectively reduced. The recombinant Bacillus subtilis of the invention can efficiently synthesize GlcNAc without affecting cell life activity, and can also limit the toxic intermediate metabolite GlcN-6-P near the plasma membrane to reduce or eliminate its inhibition on cell activity. In the process of shaking flask fermentation using complex medium, the yield of acetyl glucosamine of the control strain BSG-C was only 0.45 g.L−1, while that of BSG-AT, BSG-ATP, BSG-ATPB increased to 5.29 g.L−1, 6.22 g.L−1 and 8.48 g.L−1 respectively. The construction method of recombinant Bacillus subtilis is simple, easy to use and has a good application prospect.

Pyruvic acid is the important intermediary metabolite in biologic sugar metabolism. It has sanitarian effect and is the material of synthesizing products such as L- tryptophan, L-tyrosine and L- DOPA. This invention is a kind of method of producing pyruvic acid by dermoid hyphomycosis yeast to ferment glucose. It can get more than 40g per litre pyruvic acid from simple culture medium without adding vitamin and amino acid.

The invention relates to the field of biotechnology, especially to a gene and its application, a gene element, a method for synthesizing odd-numbered medium chain fatty aldehyde and a method for synthesizing even-numbered medium chain fatty hydrocarbon. The process of converting a precursor, namely fatty acid molecules, into an important intermediate metabolite--fatty aldehyde by the use of alpha-dioxygenase is an oxidation reaction. Extra reducing power and energy are provided without cells so as to reduce the burden of cell production. The technical limitation that fatty alcohol product chain length is only even number and fatty hydrocarbon product chain length is mostly odd number is broken. Bio-based bulk chemicals and bio-fuel molecules better match petroleum-based relative products.

The invention provides a kit and a test method for detecting catecholamine intermediate metabolites in human plasma, and the kit comprises the following reagents: (1) a calibrator solution, which is divided into calibrators with six concentrations, the calibrator with each concentration contains three catecholamine intermediate metabolites: methoxyepinephrine, methoxynoradrenaline and 3-methoxytyramine, and the calibrator solution is a solution of calibrators with six concentrations; the concentration of the calibration product is 10 pg / mL to 4000 pg / mL; (2) quality control products including a quality control product QCL, a quality control product QCM and a quality control product QCH; (3) an internal standard solution, namely a methanol solution mixed solution containing intermediate metabolites of three catecholamines; (4) a buffer solution I and a buffer solution II; (5) preparing a derivative solution; (6) leacheate; (7) an eluent; (8) a 96-hole purification plate and a 96-hole receiving plate; and (9) covering a 96-well plate with a film. The sample is treated by solid-phase extraction and then derivatization reaction, so that the detection sensitivity of the catecholamine intermediate metabolite in the sample is improved.

This invention relates to the use of naturally occurring mammalian intermediary metabolites, Tcell ligands or Tcell receptor ligands, preferably glycosylceramides, for the treatment or prevention of immune mediated or immune related diseases or disorders. Specifically, the present invention provides compositions and methods for the treatment or prevention of pulmonary, respiratory or airway diseases or disorders such as asthma.

The present invention provides a photobiological ethanol production and harvesting technology using greenhouse distillation systems with designer photosynthetic organisms, such as designer transgenic oxyphotobacteria. The designer oxyphotobacteria are created such that the endogenous photobiological regulation mechanism is tamed, and the reducing power (NADPH) and energy (ATP) acquired from the photosynthetic process are used for synthesis of ethanol (CH3CH2OH) directly from carbon dioxide (CO2) and water (H2O). The designer use of a pair of NADPH-dependent vs. NAD-dependent glyceraldehyde-3-phosphate dehydrogenases in the pathway designs offers a special cyclic “transhydrogenase” redox-shuttle function to convert NADPH to NADH for enhanced photobiological ethanol production. Through combined use of a designer photosynthetic organism with a greenhouse distillation system, the waste solar heat associated with the photobiological ethanol-production process is utilized in harvesting the produced ethanol. In addition to production and harvesting of ethanol, use of the technology can also produce intermediate metabolites and freshwater from seawater.

The invention provides a method for producing 1,3-propylene glycol with a fed-batch, and comprises a standard preparation method for seeds, followed by fermentation and cultivation. During fermentation, the relational function on the consumed dosage between the medium metabolite neutralizer and the substrate is used to control the concentration of the substrate (glycerol) in the fermentation liquid within a certain range, through adding the dosage of the substrate based on the feedback linkage with the consumed dosage of the medium metabolite neutralizer, so that neither substrate inhibition nor scarcity appears. The method can accomplish accurate feedback control on the substrate concentration of the fermentation liquid through monitoring the consumed dosage of the medium metabolite neutralizer, thereby increasing the yield of 1,3-propylene glycol. Control with singlechip or computer can be carried out during fermentation, with manual or automatic manipulation, while the investment is low with both simple operation and suitability for industrialized production.

The invention discloses an anti-blocking liquid used in surgery and a method for preparing the same. The anti-blocking liquid comprises 1 weight% carboxymethyl chitosan having molecular weight of 200000-300000 dalton and 30-100 weight% water for injection, which dynamics viscosity is 100~800 centipoise. The preparing method comprises: removing impurity protein pyrogen from the raw material; carboxymethyl-modification of chitin; purifying the carboxymethyl chitosan; preparing the anti-blocking liquid and the preparation thereof. Accordingly, the anti-blocking liquid has excellent biological barrier performance and histocompatibility, after applied on tissue wound surface, can prevent tissue tissue adhesion postoperation, which intermediary metabolite and final metabolite in human body are normal metabolites facilitating to be absorbed by the human body, without toxicity and acrimony. The anti-blocking liquid has abundance material sources with low cost and simple process, thus has broad application prospects in clinical medicine art.

The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Enz-64

The invention discloses a kit for detecting a monohydroxyphenol metabolite in urine. The kit comprises an ampoule bottle accommodated with a detection reagent, wherein the detection reagent is chitosan compound cellulose aerogel adsorbed with a color development mixture. A preparation method comprises the following steps: preparing chitosan-cellulose-chitosan aerogel hierarchically, and then adsorbing tyrosinase, tryptophanase and a color development reagent which can react with an intermediate metabolite obtained by decomposing tyrosine and tryptophan and develop a color to the aerogel through an enzyme fixing method. The kit has a specificity detection function for the trace monohydroxyphenol metabolites in the urine, and a detection method is simple, quick and high in accuracy.

Provided are polynucleotides of molecular variant promoters of the CYP2D6 gene which, for example, are associated with abnormal drug response or individual predisposition to several common diseases and disorders caused by drug under- or over-metabolization, and vectors comprising such polynucleotides. Furthermore, methods of diagnosing the status of disorders related to intermediate metabolization of drugs are described. In addition, kits comprising oligonucleotides hybridizing to the CYP2D6 promoter and / or being capable of being extended into this region useful for diagnosing subjects that are ultrarapid or intermediate metabolizer of drugs are provided.

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

Provided are polynucleotides of molecular variant promoters of the CYP2D6 gene which, for example, are associated with abnormal drug response or individual predisposition to several common diseases and disorders caused by drug under- or over-metabolization, and vectors comprising such polynucleotides. Furthermore, methods of diagnosing the status of disorders related to intermediate metabolization of drugs are described. In addition, kits comprising oligonucleotides hybridizing to the CYP2D6 promoter and / or being capable of being extended into this region useful for diagnosing subjects that are ultrarapid or intermediate metabolizer of drugs are provided.

Pyruvic acid is the important intermediary metabolite in biologic sugar metabolism. It has sanitarian effect and is the material of synthesizing products such as L- tryptophan, L-tyrosine and L- DOPA. This invention is a kind of method of producing pyruvic acid by dermoid hyphomycosis yeast to ferment glucose. It can get more than 40g per litre pyruvic acid from simple culture medium without adding vitamin and amino acid.

It is an object of the present invention to provide a bacterial strain that can decrease the amount of an intermediate Compound P converted into Metabolite M and efficiently accumulate Compound P in a medium that is not supplemented with Metabolite M or the final product generated from Metabolite M. The present invention provides a prokaryotic organism having all features (a) to (d) as defined in the specification so as to accumulate Compound P by regulating expression level of Enzyme X that converts Compound P as an intermediate metabolite into Metabolite M in a biosynthetic pathway in which Metabolite M indispensable for the growth is produced from a carbon source.

The invention relates to the technical field of synthetic biology, in particular to a genetic element, an expression vector and application of the genetic element and the expression vector. The invention provides a novel method for improving the synthesis of fatty hydrocarbon microorganisms: the fatty hydrocarbon synthesis capability of escherichia coli is improved by dynamically balancing accumulation and conversion of a key intermediate metabolite, namely fatty aldehyde. In order to achieve this purpose, ADO is helped to balance the synthesis and conversion of the fatty aldehyde through a competition path by synergistically expressing a synthesis process of fatty alcohol; then, three modules for fatty acid synthesis, lipid degradation and electron transfer, which are related to dynamic balance of the fatty aldehyde, are matched with a fatty hydrocarbon synthesis module, and finally the artificial synthesis of high-yield fatty hydrocarbon from engineering escherichia coli is realized.

The invention discloses a construction method and application of squalene-producing saccharomyces cerevisiae, and belongs to the technical field of biology. According to the invention, an auxotroph strain of S.cerevisiae BY4742 is taken as an original strain, and by optimizing an intracellular mevalonic acid pathway, the expression level of a key enzyme is enhanced and the metabolic bottleneck is relieved, so that the flux of intermediate metabolites is remarkably improved; by introducing an exogenous NADH dependent HMGR and strengthening an Acetyl-CoA supply approach, supply and demand of cofactors are effectively balanced, the availability of a precursor is improved, the yield of the constructed engineering strain AG15 fermented for 240 hours in fermentation at a 5-L fermentation tank level reaches 20.9 g / L, the production efficiency of squalene and the applicability of a carbon source are greatly improved, and the method has important industrial application potential and economic advantages.

The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.